Skip to main content

Altimmune, Inc.

corporate_fare Company Profile

Altimmune, Inc.

ALT·NASDAQ·Life Sciences·CIK 0001326190

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing new treatments for serious liver diseases. The company's main product candidate is pemvidutide (formerly ALT-801), a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Pemvidutide is being developed to treat metabolic dysfunction-associated steatohepatitis ("MASH"), alcohol use disorder ("AUD"), and alcohol-associated liver disease ("ALD"). Altimmune may also explore other uses for pemvidutide based on its clinical profile. Altimmune acquired pemvidutide through the acquisition of Spitfire Pharma Inc. in July 2019. Pemvidutide was designed as a MASH therapeutic to target both metabolic and liver-specific effects. Preclinical studies in a mouse model of MASH showed efficacy. In initial human trials, pemvidutide demonstrated weight loss and liver effects. Subsequent evaluation in participants with fatty liver disease, or metabolic-dysfunction associated liver disease (MASLD), showed significant reductions in liver fat content and weight loss. These findings led to the biopsy-driven IMPACT Phase 2b trial for MASH. The MOMENTUM Phase 2 trial in overweight and obese participants further characterized pemvidutide's effects, showing significant weight loss with relative preservation of lean muscle mass and improvements in serum lipids linked to cardiovascular disease. Beyond the recently completed IMPACT trial, pemvidutide is currently being studied in participants with AUD and ALD, with evidence suggesting it may reduce alcohol cravings and potentially reverse alcohol's harmful effects on the liver. Pemvidutide is a novel, investigational peptide.

Altimmune, Inc. (NASDAQ:ALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ALT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Altimmune Reports Strong Clinical Progress for Pemvidutide and Secures Significant Financing
  • Altimmune's Pemvidutide Gets FDA Breakthrough Status for MASH, Bolstered by $274M Cash
  • Altimmune Raises $75M via Dilutive Offering at Significant Discount to Fund Clinical Trials

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$41K
Net Income
-$88.09M
Diluted EPS
-$1.00
Op. Cash Flow
-$67.53M
Operating Income
-$94.49M
Cash & Equivalents
$43.76M
Total Debt
$34.29M
Debt / Equity
0.15×
Net Margin
-2148.61×
Shares Outstanding
110.88M sh
Source: 10-K · filed 2026-03-06 · accession 0001326190-26-000018
$1.35 +1.83% today
52-week range · as of 2026-11-12 $1.35 – $6.44
Market cap
$258.8M
Volume
4.1M (1.0× avg)
3-mo avg 4M
Live data · 2026-11-22 12:26 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALT - Filings & News (Page 2)

ALT
Mar 06, 2026, 7:56 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.60
Real-time Price: $1.35 info
Change: -$2.25 (-62%) info
Market Cap: $258.804M info
ALT
Mar 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.24
Real-time Price: $1.35 info
Change: -$2.89 (-68%) info
Market Cap: $258.804M info
ALT
Jan 28, 2026, 5:23 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.19
Real-time Price: $1.35 info
Change: -$3.84 (-74%) info
Market Cap: $258.804M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets